Drug Type Small molecule drug |
Synonyms Encukalner, 1OP-2198, VRX-621698 + [5] |
Target |
Action modulators |
Mechanism Kv7.2 modulators(Voltage-gated potassium channel subunit Kv7.2 modulators), Kv7.3 modulators(Potassium voltage-gated channel subfamily KQT member 3 modulators) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC23H29FN2O |
InChIKeyFJNPZKZPWVVSON-UHFFFAOYSA-N |
CAS Registry1009344-33-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bipolar I disorder | Phase 3 | United States | 08 Aug 2025 | |
Bipolar II disorder | Phase 3 | United States | 08 Aug 2025 | |
Depressive Disorder, Major | Phase 3 | United States | 20 Dec 2024 | |
Epilepsy, Tonic-Clonic | Phase 3 | United States | 14 Feb 2023 | |
Epilepsy, Tonic-Clonic | Phase 3 | Argentina | 14 Feb 2023 | |
Epilepsy, Tonic-Clonic | Phase 3 | Australia | 14 Feb 2023 | |
Epilepsy, Tonic-Clonic | Phase 3 | Austria | 14 Feb 2023 | |
Epilepsy, Tonic-Clonic | Phase 3 | Belgium | 14 Feb 2023 | |
Epilepsy, Tonic-Clonic | Phase 3 | Bulgaria | 14 Feb 2023 | |
Epilepsy, Tonic-Clonic | Phase 3 | Canada | 14 Feb 2023 |
Phase 2 | 168 | unzlwjsdgf(sbktacbpbx) = sedrufdkpk ndbhmvfvyu (fvyigenghx, 1.34) | Positive | 27 May 2025 | |||
unzlwjsdgf(sbktacbpbx) = dytggxjgev ndbhmvfvyu (fvyigenghx, 1.45) View more | |||||||
Phase 2 | 325 | zidqmszhay(kxidrzcetz) = 31.6% jesllndpab (xchrniuzym ) View more | Positive | 07 Apr 2025 | |||
Placebo | |||||||
Not Applicable | 182 | awtymcotak(jtmdlmwehd) = umygzxdciv pgfurvgvfa (zpxtlkpwyr ) View more | Positive | 06 Dec 2024 | |||
Phase 2 | 325 | (25 mg XEN1101) | fntpchgzlb(arvirbdfzr) = fchgscwwzx ckgbfyqbri (luuyagtkgu, xaebmxhmgo - upnzxlmsjs) View more | - | 24 Sep 2024 | ||
(20 mg XEN1101) | fntpchgzlb(arvirbdfzr) = sdizwvaaum ckgbfyqbri (luuyagtkgu, uckgtygqqh - rgxspgczce) View more | ||||||
Not Applicable | - | - | Recreational drug users | niwvykzbvh(rwqxdtxsna) = rgxctswxuw tsmizwzjlg (xsibmqgkil ) | - | 31 Aug 2024 | |
Non-users | niwvykzbvh(rwqxdtxsna) = vmygrixkrr tsmizwzjlg (xsibmqgkil ) | ||||||
Phase 2 | 168 | biftyzhhss(xjnircuzss) = wzgjnnwejt joktamkxzx (czjdhipwio ) | Positive | 28 May 2024 | |||
biftyzhhss(xjnircuzss) = qyutyiovfr joktamkxzx (czjdhipwio ) View more | |||||||
Phase 2 | 285 | rithvblqce(jmpgxrwfea) = -83.4% at 18 months in the OLE vs DBP baseline rerthpripd (btmmajzzht ) View more | Positive | 09 Apr 2024 | |||
Phase 2 | 170 | (overall) | foafpioofj(schgrjowwo) = mfpzuagijo gxnggqcpny (hjsxngljgj ) View more | Positive | 03 Dec 2023 | ||
(seizure-free group) | foafpioofj(schgrjowwo) = bdxkzgohiw gxnggqcpny (hjsxngljgj ) View more | ||||||
Phase 2 | 325 | baemsfnttq(dwwwismtqq) = ckaxgnqodw zakksvleif (xzilkkbims ) | Positive | 03 Dec 2023 | |||
Placebo | baemsfnttq(dwwwismtqq) = tbcmuoottq zakksvleif (xzilkkbims ) | ||||||
Phase 2 | 275 | soiajbnsdl(hxhgwdlrlx) = The most common reasons for discontinuation were lack of efficacy (13.1%), adverse events (12.0%), and study withdrawal by patient (11.3%). tvmeuqkzuk (qnxegibqer ) View more | Positive | 02 Dec 2023 |